# US 12,006,365 B2 · Human anti-semaphorin 4D antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,006,365 B2
- Document ID: US12006365B2
- Status: Granted
- Kind: B2
- Application number: 17/813,375
- Filed: 2022-07-19
- Published: 2022-11-10
- Granted: 2024-06-11
- Earliest claimed: 2017-05-05
- Assignees: Vaccinex, Inc.
- Applicants: Vaccinex, Inc.
- Inventors: Ernest S. Smith; Angelica Cornelison; Maria Scrivens; Mark Paris; Maurice Zauderer
- Web page: https://patentgrep.com/patent/US12006365B2

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K 2039/505: {comprising antibodies}
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.

## Claims

### Claim 1

A composition comprising an antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises complementarity determining regions (HCDRs) HCDR1, HCDR2, and HCDR3 comprising amino acid sequences SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, respectively; and wherein the VL comprises complementarity determining regions (LCDRs) LCDR1, LCDR2, and LCDR3 comprising amino acid sequences SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, respectively; and
wherein the VH comprises an amino acid sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 1 and/or the VL comprises an amino acid sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 5.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the VH further comprises framework regions (HFWs) HFW1, HFW2, HFW3, and HFW4, and wherein the VL further comprises framework regions (LFWs) LFW1, LFW2, LFW3, and LFW4.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the framework regions are human antibody framework sequences.

### Claim 4 (depends on 2)

The composition of claim 2, wherein the framework regions are non-human antibody framework sequences.

### Claim 5 (depends on 1)

The composition of claim 1, further comprising a heavy chain constant region or fragment thereof fused to the C-terminus of the VH.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the heavy chain constant region or fragment thereof is a human heavy chain constant region.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the heavy chain constant region or fragment thereof is a human IgG4 constant region.

### Claim 8 (depends on 5)

The composition of claim 5, wherein the heavy chain constant region or fragment thereof is a non-human heavy chain constant region.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the heavy chain constant region or fragment thereof is a murine IgG1 constant region.

### Claim 10 (depends on 1)

The composition of claim 1, further comprising a light chain constant region or fragment thereof fused to the C-terminus of the VL.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the light chain constant region or fragment thereof is a human light chain constant region.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the light chain constant region or fragment thereof is a human lambda light chain constant region.

### Claim 13 (depends on 10)

The composition of claim 10, wherein the light chain constant region or fragment thereof is a non-human light chain constant region.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the light chain constant region or fragment thereof is a murine lambda light chain constant region.

### Claim 15 (depends on 1)

The composition of claim 1, which is an Fab fragment, an Fab′ fragment, an F(ab′)2 fragment, an Fd fragment, a single-chain Fv fragment (scFv), or a disulfide-linked Fv fragment (sdFv).

### Claim 16 (depends on 1)

The composition of claim 1, which is multispecific.

### Claim 17 (depends on 1)

A method for neutralizing SEMA4D in a human subject, comprising administering to the human subject the composition of claim 1.

### Claim 18 (depends on 1)

A method of treating cancer in a subject, comprising administering to the subject the composition of claim 1.

### Claim 19 (depends on 18)

The method of claim 18, wherein the cancer is a solid tumor that expresses Semaphorin 4D (SEMA4D) or a SEMA4D receptor.

### Claim 20 (depends on 18)

The method of claim 18, wherein the method further comprises administering another anti-cancer antibody therapy, a small molecule-based cancer therapy, or a vaccine/immunotherapy-based cancer therapy to the subject.

### Claim 21 (depends on 20)

The method of claim 20, wherein the composition and the anti-cancer antibody therapy, the small molecule-based cancer therapy or the vaccine/immunotherapy-based cancer therapy are co-administered or administered separately.

### Claim 22 (depends on 1)

The composition of claim 1, further comprising an immunosuppressive or anti-inflammatory agent.

### Claim 23 (depends on 17)

The method of claim 17, wherein the subject has an autoimmune disease or disorder, an inflammatory disease or disorder, cancer, a neuroinflammatory disease or disorder, a neurodegenerative disease or disorder, or any combination thereof.

### Claim 24 (depends on 23)

The method of claim 23, wherein the method further comprises administering an immunosuppressive agent or anti-inflammatory agent.

### Claim 25 (depends on 23)

The method of claim 23, wherein the method further comprises administering an anti-cancer antibody therapy, a small molecule-based cancer therapy or a vaccine/immunotherapy-based cancer therapy.

### Claim 26 (depends on 23)

The method of claim 23, wherein the autoimmune disease is an osteodegenerative disease.

### Claim 27 (depends on 1)

The composition of claim 1, wherein the antibody or antigen-binding fragment thereof inhibits binding of SEMA4D to its receptor.